2014 - 2017 未治療原発不明癌に対する次世代シークエンスを用いた原発巣推定に基づく治療 効果の意義を問う第 II 相試験
論文 (281件):
Hidetoshi Hayashi, Kenji Chamoto, Ryusuke Hatae, Takashi Kurosaki, Yosuke Togashi, Kazuya Fukuoka, Megumi Goto, Yasutaka Chiba, Shuta Tomida, Takayo Ota, et al. Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade. Journal of Clinical Investigation. 2024
Koji Haratani, Atsushi Nakamura, Nobuaki Mamesaya, Kenji Sawa, Yoshimasa Shiraishi, Ryota Saito, Junko Tanizaki, Yosuke Tamura, Akito Hata, Kosuke Tsuruno, et al. Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer. British journal of cancer. 2024
Satoru Hagiwara, Junko Tanizaki, Hidetoshi Hayashi, Yoriaki Komeda, Naoshi Nishida, Akihiro Yoshida, Tomoki Yamamoto, Takuya Matsubara, Masatoshi Kudo. Hemophagocytic lymphohistiocytosis induced by nivolumab/ipilimumab combination therapy: A case of lung adenocarcinoma that responded to early steroid pulse therapy. Cancer reports (Hoboken, N.J.). 2024. e1960
Junko Tanizaki, Hidetoshi Hayashi. Unraveling Pseudo Kidney Injury: The Significance of Understanding Our “MATE” in Molecular-Targeted Therapies. Journal of Thoracic Oncology. 2024
Yoshimasa Shiraishi, Junji Kishimoto, Shunichi Sugawara, Hideaki Mizutani, Haruko Daga, Koichi Azuma, Hirotaka Matsumoto, Osamu Hataji, Kazumi Nishino, Masahide Mori, et al. Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. JAMA oncology. 2023